ArticleAnnals of intensive care2019
Candidemia in critically ill immunocompromised patients: report of a retrospective multicenter cohort study.
Article in Annals of intensive care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 61 citations in OpenAlex.
- Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial.Antimicrobial agents and chemotherapy · 2023Trial
- Epidemiology of source-related candidaemia and breakthrough candidaemia in intensive care units.BMC infectious diseases · 2026Article
- Clinical and microbiological epidemiology of Candida infections in a high-complexity hospital in Tolima, Colombia (2014-2024).PloS one · 2026Observational
- Invasive candidiasis in intensive care medicine: shaping the future of diagnosis and therapy.Intensive care medicine · 2025Review
- Article
- Development of Melting-Curve-Based Real-Time PCR for Differentiating Medically ImportantInternational journal of molecular sciences · 2025Article
- Improved Sixty-Day Mortality in Candidemia with Antifungal Treatment Within 72 Hours of Fever Onset: A Single-Center Retrospective Study in Rural Japan.Infectious disease reports · 2025Article
- A Comparative Review of Eugenol and Citral Anticandidal Mechanisms: Partners in Crimes Against Fungi.Molecules (Basel, Switzerland) · 2024Review
- Oral Mycobiome Alterations in Postmenopausal Women: Links to Inflammation, Xerostomia, and Systemic Health.Biomedicines · 2024Review
- Biofilm formation and drug susceptibility of biofilmIranian journal of microbiology · 2024Article
- Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia.The Journal of antimicrobial chemotherapy · 2024Article
- Study on the inhibitory effect of fermentation extract of Microporus vernicipes on Candida albicans.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Article
- Fungal infections in immunocompromised critically ill patients.Journal of intensive medicine · 2024Review
- Establishment and Validation of a Nomogram Clinical Prediction Model for Nosocomial Candidemia: An 18-Year Retrospective Analysis.Infection and drug resistance · 2024Article
- [Feature analysis of different neutrophil levels on the distribution of pathogens in bloodstream infection in patients with hematologic malignancy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Evaluation of Fluconazole versus Echinocandins for Treatment of Candidemia Caused by Susceptible CommonJournal of fungi (Basel, Switzerland) · 2023Article
- Anaerobic conditions are a major influence on Candida albicans chlamydospore formation.Folia microbiologica · 2023Article
- Alterations in the Level of Ergosterol inInternational journal of molecular sciences · 2023Article
- Synthetic Glycans to Improve Current Glycoconjugate Vaccines and Fight Antimicrobial Resistance.Chemical reviews · 2022Review
- Novel Chromogenic Medium CHROMagarJournal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunocompromised critically ill patients constitute a population with the high risk of candidemia. This retrospective study aimed to assess the outcome of immunocompromised critically ill patients with candidemia. Secondary objectives were to describe clinical phenotypes of these patients, Candida ecology, and factors associated with mortality.
resultsOverall, 121 patients were included in this study. Median delay from candidemia to first antifungal therapy was 3 days, in line with the observed delay of blood culture positivity. Candia albicans was the main Candida specie identified (54%), and susceptibility of Candida to fluconazole and echinocandins was of, respectively, 70% and 92%. Hospital mortality was of 60%. After adjustment for confounders, severity as assessed by the need for vasopressors (HR 1.8, CI95% 1.1-3.1), need for mechanical ventilation (HR 2.0, CI95% 1.1-3.8) and allogenic stem cell transplantation (HR 2.5, CI95% 1.1-6.0) were independently associated with poor outcome. Candida specie, susceptibility and treatment strategies were not associated with outcome.
conclusionsCandidemia in immunocompromised critically ill patients is associated with a grim outcome. Despite the high prevalence of Candida non-albicans species, neither C. species nor its susceptibility was associated with outcome. Conversely, severity and preexisting allogeneic stem cell transplantation were independently associated with poor outcome. Despite antifungal prophylaxis and use of preemptive antifungal therapy in neutropenic patients, antifungal therapy was initiated three days after symptoms onset suggesting needs for specific strategies aiming to reduce this delay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.